dmc1:dmc2:Array ( )
dmc1 cat array 0: PT:page
Array ( )

ICP Monitoring, & Maintenance & Reduced Risk of Infection

Elevated ICP is a common cause of neurological damage and death in patients with any neurosurgical intracranial pathology. Continuous ICP monitoring and catheter drainage of cerebrospinal fluid (CSF) or pathological intracranial fluid in order to lower ICP is consequently important to patient outcomes. Using conventional draining systems, both the above functions are frequently interrupted by catheter blockage, thus putting patient outcome at risk as attempts to unblock the catheter increases infection risk and are often unsuccessful, leading to reoperations for new catheter insertions.

IRRAflow Treatment Advantages

The IRRAflow system offers significant treatment advantages over conventional ICP monitoring and drainage systems with more safety, reliability and efficacy, through the integration of aspiration, targeted infusion and precise intracranial pressure monitoring in a single robust, intelligent device. IRRAflow’s proprietary product features enable intelligent intracranial fluid management as well as accurate, real-time monitoring of ICP, with minimized risk of catheter blockage and associated infection risk. Since the commercial launch of IRRAflow in May 2017, IRRAflow has been used successfully in numerous hemorrhagic stroke/chronic subdural hematoma cases in Germany and Austria with no reported incidents of catheter blockage or associated infection.

Significant Health Economic Benefits

IRRAflow has demonstrated health economic benefits since its commercial launch in the EU. IRRAflow has been used in patient treatments with positive clinical outcomes on shorter treatment timelines than conventional drainage devices, resulting in estimated saved costs of between EUR 4,300 and EUR 7,700 per patient1. Open surgery and inadequate monitoring of the ICP in many cases leads to increased complications for the patient and an increased risk of negative outcomes, resulting in a severe decrease in quality of life and further costs to society as a result of loss of productivity and the additional care required after hospital discharge.

1 Based on [∙] procedures performed with IRRAflow for the treatment of hemorrhagic stroke/chronic subdural hematoma following commercial launch in May 2017 through [September 30], 2017. The low end of the average savings range, EUR 4,300, is compared with patients treated with a conventional EVD where a catheter exchange was unnecessary; the high end of the average savings range, EUR 7,700, is compared with patients treated with a conventional EVD where a catheter exchange was necessary due to blockage. The comparison includes the costs of the consumables used, but not the cost of the IRRAS control unit. Length of stay is based on data from Universitätskliniken Lübeck and Rostock, Germany. Treatment costs are based on data from DIMDI.